By Sabela Ojea

AstraZeneca PLC said Friday that the Propel Phase 3 trial met its primary point, proving that its Lynparza drug significantly delayed disease progression of first-line metastatic castration-resistant prostate cancer in combination with the abiraterone drug.

The biopharmaceutical company said the results from the trial showed positive results, including a trend towards improved overall survival.

The London-listed company noted that prostate cancer is the second most common cancer.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

09-24-21 0231ET